Mike Kratky
Stock Analyst at Leerink Partners
(3.61)
# 869
Out of 4,734 analysts
26
Total ratings
55.56%
Success rate
39.92%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $84.38 | +3.11% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $177.68 | +10.87% | 2 | Sep 10, 2024 | |
| TXG 10x Genomics | Initiates: Outperform | $35 | $15.08 | +132.10% | 1 | Sep 3, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $263.69 | -0.26% | 1 | Sep 3, 2024 | |
| NARI Inari Medical | Initiates: Market Perform | $47 | $79.55 | -40.92% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $35.15 | +28.02% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $11.97 | +83.79% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $275.81 | -33.29% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $59.07 | -28.90% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $592.64 | -42.29% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $69.78 | +7.48% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $76.02 | -51.33% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $18.09 | -50.25% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $5.13 | +874.85% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $11.21 | +301.43% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $293.64 | +7.27% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $40.61 | -23.66% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $23.86 | -41.32% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $18.13 | +120.63% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $1.20 | +3,900.00% | 1 | Aug 11, 2022 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $84.38
Upside: +3.11%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $177.68
Upside: +10.87%
10x Genomics
Sep 3, 2024
Initiates: Outperform
Price Target: $35
Current: $15.08
Upside: +132.10%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $263.69
Upside: -0.26%
Inari Medical
Sep 3, 2024
Initiates: Market Perform
Price Target: $47
Current: $79.55
Upside: -40.92%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $35.15
Upside: +28.02%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $11.97
Upside: +83.79%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $275.81
Upside: -33.29%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $59.07
Upside: -28.90%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $592.64
Upside: -42.29%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $69.78
Upside: +7.48%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $76.02
Upside: -51.33%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $18.09
Upside: -50.25%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $5.13
Upside: +874.85%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $11.21
Upside: +301.43%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $293.64
Upside: +7.27%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $40.61
Upside: -23.66%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $23.86
Upside: -41.32%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $18.13
Upside: +120.63%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $1.20
Upside: +3,900.00%